sildenafil / Generic mfg. - LARVOL DELTA

ShenRongGuBenHuanShao Pill Ameliorates Hydrocortisone-Induced Erectile Dysfunction: Insights from Integrated Multi-Omics Analysis. (PubMed, Pharmaceuticals (Basel)) - "Rats exposed to HC received SRGBHSP (1.08, 2.16, or 4.32 g/kg), Yougui Pill, or sildenafil concurrently with HC administration. Flavonoids may represent important bioactive constituents associated with the observed effects of SRGBHSP. Overall, this study provides an integrated pharmacological and multi-omics framework for understanding the effects of SRGBHSP on HC-associated ED-related alterations."

Journal • Erectile Dysfunction • Metabolic Disorders • AKT1

SILDYS: Vaginal Sildenafil for Primary Dysmenorrhea (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Kevin Hellman | N=50 ➔ 10 | Trial completion date: Oct 2027 ➔ Jul 2027 | Initiation date: May 2026 ➔ Oct 2026

Enrollment change • Trial completion date • Trial initiation date • Endometriosis • Gynecology • Pain • Solid Tumor • Uterine Leiomyoma • Women's Health

Reliability and agreement between alternative CO2 paradigms for assessment of cerebrovascular reactivity in cerebral small vessel disease. (PubMed, Physiol Meas) - "In 75 CSVD patients in the placebo-controlled, crossover OxHARP trial of sildenafil, agreement and reproducibility of baseline (1 st visit) and placebo visit CVR was derived comparing 4% and 6% CO2 exposure...CVR assessments were reproducible, but this reliability was influenced by CO₂ dose and the analytical approach. While single-point measurements showed the best inter-and intra-participant variability, overall, CVR estimation using a GLM demonstrated a superior test-retest reliability across visits."

Journal

Dual Phosphodiesterase-5 Inhibitor-Induced Gastric Stasis Leading to Esophageal Variceal Hemorrhage: A Cautionary Case (ACG 2026) - "Case Description/ A 56-year-old male with Child-Pugh Class B alcoholic cirrhosis MELD 3.0 14 presented with large-volume hematemesis after forceful vomiting 72 hours after taking his prescribed 20mg tadalafil dose and self-medicating with 50mg sildenafil. Figure: Figure 2. Grade II esophageal varices with stigmata of bleeding."

Clinical • Cardiovascular • Erectile Dysfunction • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Hypotension • Immunology • Liver Cirrhosis • Portal Hypertension • CYP3A4

A Tale of Opposing Pulmonary Vascular Complications in a Cirrhotic Patient (ACG 2026) - "She was treated with intravenous diuresis and sildenafil but experienced increased oxygen requirements as well as new platypnea and orthodeoxia...The underlying cause is unknown, but previous case reports have hypothesized the use of vasodilators as the precipitating cause for HPS development. Figure: Schematic representation of the divergent pulmonary vascular consequences of portal hypertension"

Clinical • Cardiovascular • Fibrosis • Hepatology • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Liver Cirrhosis • Portal Hypertension • Primary Biliary Cholangitis • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis

SERIES: Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT) (clinicaltrials.gov) - P2/3 | N=100 | Completed | Sponsor: Sindh Institute of Cardiovascular Diseases | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Apr 2026 ➔ Sep 2026

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Quercetin enhances the renoprotective effects of phosphodiesterase inhibitors by attenuating endoplasmic reticulum stress-induced cellular apoptosis via modulation of GRP75/CHOP/Bax/Bcl2 pathway. (PubMed, Histochem Cell Biol) - "This study investigated the ability of quercetin (QU) alone or with sildenafil (Sild) or pentoxifylline (PTX) to modulate carbon tetrachloride (CCl4)-induced renal fibrosis in Wistar albino rats. The combination of QU with Sild or PTX resulted in greater renoprotection by regulating several key pathways, including reductions in ER stress, enhanced antioxidative defenses, and regulation of apoptosis. In conclusion, a combination of QU with Sild or PTX ameliorates renal fibrosis by inhibiting ER stress-induced cellular apoptosis through modulation of the GRP75/CHOP/Bax/Bcl2 and oxidative stress pathways."

IO biomarker • Journal • Fibrosis • Immunology • Inflammation • Renal Disease • BAX • BCL2 • HSPA9

Use of drug information resources, knowledge, and competence for managing medication related problems: results of a community pharmacy survey in Egypt. (PubMed, Int J Pharm Pract) - "Community pharmacists and pharmacy students/trainees in Egypt reported frequent use of digital DI resources; however, their knowledge and performance remained moderate. Formal training was associated with better performance, highlighting the need to strengthen education and continuing professional development through collaboration between educational institutions and professional bodies."

Journal

Biochemical and clinical effects of continuous positive airway pressure combined with sildenafil on inflammatory and hemodynamic profiles in obese asthma patients with pulmonary arterial hypertension. (PubMed, J Med Biochem) - "CPAP combined with sildenafil exerts dual biochemical and clinical benefits in obese asthma patients with PAH by enhancing oxygenation, lowering pulmonary artery pressure, and suppressing inflammatory cytokine activity. The observed reductions in IL-6, TNF-α, and FeNO highlight the biochemical basis of treatment efficacy and the potential of these markers as laboratory indicators for monitoring therapeutic outcomes."

Journal • Asthma • Cardiovascular • Genetic Disorders • Hypertension • Immunology • Obesity • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • IL6 • TNFA

Anti-remodelling effects of formyl peptide receptor agonism in a novel precision-cut lung slice model of pulmonary arterial hypertension (ERS 2026) - " PCLS from agarose-inflated lungs were treated with a pulmonary hypertension cocktail (PHC=TNFα, TGF-β, PDGF-AB, ET-1) ± FPR agonist (Cmpd17b, BMS-986235), sildenafil, iloprost or nintedanib (hPCLS only)... Our novel PCLS model mimics phenotypic changes in PAH. Different FPR agonists show varied inhibition of PHC-induced inflammation, fibrogenesis and vascular remodelling in mPCLS and hPCLS. FPR agonism may modify disease progression in PAH, more comprehensively than current therapies."

Cardiovascular • Inflammation • Pulmonary Arterial Hypertension • Respiratory Diseases • IL6 • TGFB1 • TNFA

Clinical efficacy of pharmacological treatments for idiopathic pulmonary fibrosis: a systematic literature review (ERS 2026) - "Eighteen trials assessed pirfenidone (PIR) or nintedanib (NIN) as monotherapy...By treatment group, mCFB values were −30.9 to −95 mL with NIN 150 mg twice daily (NIN-150BID); −115 mL with nerandomilast 18 mg; −235 mL with PIR 2403 mg/day; and −183.5 to –428 mL with placebo (PBO)...Acute exacerbation rates over 52 weeks ranged 0%–33% across 7 trials, with NIN-150BID, 0%–6.1%; NIN-150BID + PIR 1200–1800 mg/day, 33%; PIR 2403 mg/day, 4%; PIR 2403 mg/day + sildenafil 60 mg/day, 11%; and PBO, 1.8%–15.7%... Variable efficacy of current therapies on lung function and acute exacerbations highlights the unmet need for better IPF therapies."

Clinical • Review • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE (ISPOR 2026) - "DTC pharmacies such as MCCPDC meaningfully lower out-of-pocket costs for higher-cost generic prescriptions which could otherwise be difficult to afford. Commercially insured patients should consider DTC pharmacies when their copayment or coinsurance for a generic medication exceeds $15, and particularly when it exceeds $100."

Clinical • Reimbursement • US reimbursement • CNS Disorders • Depression • Endocrine Disorders • Erectile Dysfunction • Multiple Sclerosis

Assessing the therapeutic potential of PDE-5 inhibitors in adults: Insights from a multi-omics study. (PubMed, Physiol Rep) - "Sixteen men and women aged 50-60 were administered daily sildenafil/tadalafil for 1 month. However, this did not translate to immunohistochemical changes. Additional research is warranted to investigate PDE-5 inhibitor effects on various tissues, which can inform prospective applications for drug repurposing."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Oncology

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension. (PubMed, Br J Clin Pharmacol) - "The CYP3A5*3 allele is associated with higher sildenafil exposure and superior clinical outcomes. Therefore, CYP3A5 genotyping may facilitate personalized assessment of sildenafil efficacy and clinical outcomes."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • CYP3A5

PDE5 inhibition restores mitochondrial function and improves neurobehavioral outcomes after repeated mild blast TBI. (PubMed, Neurotherapeutics) - "At 20 weeks, rmbTBI animals exhibited persistent fear-conditioned behavior, whereas sildenafil facilitated fear extinction. These findings demonstrate that rmbTBI disrupts mitochondrial function and behavior, and that PDE5 inhibition with sildenafil restores these alterations, supporting its potential as a therapeutic intervention for blast-induced TBI."

Journal • CNS Disorders • Metabolic Disorders • Psychiatry • Vascular Neurology

First-in-Human Remote Pulmonary Haemodynamic Monitoring in PH-ILD: Feasibility and Treatment Response Using Implantable Sensors (ERS 2026) - "Methods We observed the acute and chronic effects of sildenafil given as standard of care in seven patients with PH-ILD and pulmonary artery pressure and insertable cardiac monitors (FIT-PH/IRAS269248/STH20422)...Figure 1. Demographics table"

First-in-human • P1 data • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension

Intravenous magnesium sulfate combined with targeted pulmonary vasodilators in preterm infants with bronchopulmonary dysplasia and associated pulmonary hypertension: a case series and literature review (ERS 2026) - "All received sildenafil; milrinone added in three cases due to right ventricular dysfunction (RVD) or suboptimal response. Adjunctive MgSO₄ combined with targeted pulmonary vasodilation was well tolerated and associated with respiratory and echocardiographic improvement. These data generate the hypothesis that combined bronchodilator and pulmonary vasodilator therapy could modify short-term cardiorespiratory trajectories in this high-risk neonatal population. Prospective controlled studies are needed to define efficacy, optimal dosing and safety."

Clinical • Prematurity • Review • Bronchopulmonary Dysplasia • Cardiovascular • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Impact of oral sildenafil on exercise capacity in mild-to-moderate chronic obstructive pulmonary disease: a randomized placebo-controlled cross-over trial (ERS 2026) - "Despite modest reductions in RVSP, preliminary results suggest that oral sildenafil did not improve exercise capacity, ventilatory efficiency, or dyspnea in patients with mild to moderate COPD, which may reflect phenotypic heterogeneity in pulmonary vascular structure and function."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Evolving Respiratory Phenotype in Children with ACTA2-Related Smooth Muscle Dysfunction: Beyond Rapidly Progressive Infantile ILD (ERS 2026) - "Intermittent pulmonary hypertension occurred during acute illnesses, managed temporarily with sildenafil, later discontinued with no baseline pulmonary hypertension... Recognition of this evolving respiratory phenotype is crucial to avoid missing ACTA2-related disease and to appreciate its broader spectrum beyond rapidly progressive ILD as previously described. Evidence for disease-modifying therapy is lacking, highlighting the need for longitudinal studies to guide monitoring and management."

Clinical • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Interstitial Lung Disease • Ophthalmology • Pulmonary Arterial Hypertension • ACTA2

Comparison of sildenafil and tadalafil in pulmonary arterial hypertension: A retrospective, propensity score matched analysis (ERS 2026) - "These findings may reflect differences in compliance, tolerance, or pharmacokinetics. Head-to-head RCTs are needed to confirm these findings."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Respiratory Diseases

Association of higher doses of sildenafil and survival in pulmonary arterial hypertension (ERS 2026) - "Higher doses of sildenafil are independently associated with improved survival in PAH patients, regardless of the use of combination therapy. These results suggest that optimizing sildenafil dosing may be a strategy for improving long-term clinical outcomes."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Pocket-PH: The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2/3 | N=20 | Recruiting | Sponsor: Silvia Ulrich

New P2/3 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Pia Wintermark | Trial completion date: Jun 2028 ➔ Oct 2031 | Trial primary completion date: Oct 2027 ➔ Oct 2030

Trial completion date • Trial primary completion date • CNS Disorders • Vascular Neurology

COMPARATIVE OUTCOME OF SILDENAFIL VS NITRAATE TREATMENT IN ANGINA: A PROPENSITY MATCHED COHORT STUDY (CHEST 2026) - No abstract available

Cardiovascular

Sensorineural Hearing Loss and Phosphodiesterase-5 Inhibitors: A Systematic Review. (PubMed, Int Arch Otorhinolaryngol) - "Sildenafil, vardenafil, and tadalafil were the most commonly used PDE-5is. The current systematic review underscores the importance of monitoring hearing in PDE5i patients and advising them about the potential risk. Further research with larger samples and control groups is needed to establish a definitive causal link."

Journal • Review • Otorhinolaryngology • Vertigo